Abstract
The potent suppression of adipocyte differentiation by 4-(4-methylbenzamino)benzoate was discovered during the search for new antiobesity compounds. 4-(4-methylbenzamino)benzoate was observed to suppress adipocyte differentiation in 3T3-L1 cells by 96.8% at 50 μM without cytotoxicity. In addition, 4-(4-methylbenzamino)benzoate reduced the cellular expression of fatty acid synthase in a concentration-dependent manner, as well as suppressing PPAR-gamma activity, which controls fatty acid storage and glucose metabolism. Based on these results, 4-(4-methylbenzamino)benzoate shows potential as an antiobesity material.
Highlights
A major factor in the development of heart disease, cancer, hypertension, diabetes, and degenerative arthritis, is induced by adipocyte differentiation due to hormonal changes and imbalances in energy metabolism caused by excessive fat intake [1,2,3,4,5]
Adipogenesis in the body is the process of cell differentiation by which preadipocytes become adipocytes during fat accumulation
The MTT assay showed that MBAB did not cause significant cell death at a concentration
Summary
A major factor in the development of heart disease, cancer, hypertension, diabetes, and degenerative arthritis, is induced by adipocyte differentiation due to hormonal changes and imbalances in energy metabolism caused by excessive fat intake [1,2,3,4,5]. Studies have shown that natural compounds, resveratrol and genistein, have antiobesity effects [8,9,10,11]. The potent adipogenesis-suppressing activity of 4-(4-methylbenzamino)benzoate (MBAB, Figure 1) was observed in 3T3-L1 cells without cytotoxicity, during the search for new antiobesity substances. MBAB exhibited higher adipogenesis-suppressing activity compared to resveratrol or genistein.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
